Cardio-oncology & otherCohort study
Recombinant shingles vaccination and the risk of cardiovascular events
- Natural experiment cohort study
Study context
- Population
- US adults aged ≥60 years vaccinated against shingles
- Exposure
- Recombinant vs live attenuated shingles vaccine
- Outcome
- Composite CV endpoint:
- Ischemic heart disease
- HF
- Ischemic stroke
- Follow-up
- 7 years
Main finding
Composite CV burden
Restricted mean time lost (RMTL) ratio
0.91
95% CI 0.88–0.95
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Estimate |
|---|---|
| Ischemic heart disease · 10% decrease in burden; both sexes | RMTL ratio 0.90 (95% CI 0.87–0.94) |
| HF · 12% decrease in burden; both sexes | RMTL ratio 0.88 (95% CI 0.83–0.93) |
| Ischemic stroke (males) · 12% decrease | RMTL ratio 0.88 (95% CI 0.78–0.98) |
| AF · 7% decrease in burden | RMTL 0.93 (95% CI 0.88–0.98) |
Other cardiac, peripheral and cerebrovascular outcomes
- No association
Secondary analyses
- Results consistent
Original publication
Recombinant shingles vaccination and the risk of cardiovascular events. Nat Med. Published 26 August 2026. doi:10.1038/s41591-026-04606-0
Summarised from the published abstract; every number is checked against it